NFATc1-IN-1

CAS No. 1912422-56-0

NFATc1-IN-1( —— )

Catalog No. M35568 CAS No. 1912422-56-0

NFATc1-IN-1 (also known as compound A04) is a highly effective inhibitor of osteoclast formation induced by RANKL, with an IC50 of 1.57 μM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 45 Get Quote
10MG 76 Get Quote
25MG 150 Get Quote
50MG 227 Get Quote
100MG 335 Get Quote
500MG 782 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    NFATc1-IN-1
  • Note
    Research use only, not for human use.
  • Brief Description
    NFATc1-IN-1 (also known as compound A04) is a highly effective inhibitor of osteoclast formation induced by RANKL, with an IC50 of 1.57 μM.
  • Description
    NFATc1-IN-1 (compound A04) is a potent inhibitor of RANKL-induced osteoclast formation, with an IC50 of 1.57 μM. NFATc1-IN-1 shows anti-osteoclastogenic effects through reducing the RANKL-induced nuclear translocation of NFATc1. NFATc1-IN-1 can be used for osteoclastic diseases research.
  • In Vitro
    NFATc1-IN-1 (compound A04) (0-2.5 μM, 4 days) exhibits potent inhibitory activities on osteoclast formation and function, which eventually translates into decreased bone resorption.NFATc1-IN-1 (1.5-2.5 μM, 24 h) blocks NFATc1 nuclear translocation and decreases the level of NFATc1Cell Viability Assay Cell Line:Osteoclast precursor RAW 264.7 cells Concentration:0, 0.5, 1.0, 1.5, 2.0 and 2.5 μM Incubation Time:4 days Result: Markedly reduced the number and size of red TRAP-positive multinucleated osteoclasts at concentrations of 1.5, 2.0, and 2.5 μM. Significantly inhibited formation of osteoclasts in a dose-dependent manner (at 1.5, 2.0 and 2.5 μM), while showing no cytotoxic effects towards osteoclast precursor cells at concentrations of as high as 2.5 μM.Immunofluorescence Cell Line:RAW264.7 cells Concentration:1.5 or 2.5 μM Incubation Time:24 h Result:Blocked NFATc1 nuclear translocation and decreased the level of NFATc1.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    RANKL/RANK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1912422-56-0
  • Formula Weight
    375.11
  • Molecular Formula
    C13H8F2INO2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (333.24 mM; Ultrasonic )
  • SMILES
    C(NC1=C(F)C=C(I)C=C1)(=O)C2=C(O)C=CC(F)=C2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Chen CL, et al. Design, synthesis and SARs of novel salicylanilides as potent inhibitors of RANKL-induced osteoclastogenesis and bone resorption. Eur J Med Chem. 2016 Jul 19;117:70-84.?
molnova catalog
related products
  • (S,R,S)-AHPC-PEG3-NH...

    (S,R,S)-AHPC-PEG3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.

  • Mal-PEG2-C2-Boc

    Mal-PEG2-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

  • MKI-1

    MKI-1 (MASTL Kinase Inhibitor-1) is an inhibitor of MASTL (microtubule-associated serine/threonine kinase-like, IC50= 9.9 μM).